15
Phase 2–4 trials
KRAS inhibitors · Live ClinicalTrials.gov data
Adagrasib (Krazati) clinical trial pipeline
ClinicalTrials.gov lists 15 phase 2–4 trials for adagrasib (Krazati), 5 of them actively recruiting. The next phase 3 primary completion among them is expected Sept 2029. Refreshed daily. Add up to four competitors to compare pipelines side by side.
4
Phase 3 trials
5
Actively recruiting
Sept 2029
Next phase 3 primary completion
3,704
Participants across trials
Mirati Therapeutics Inc.
Lead sponsor by trial count
adagrasib (15)15 active2019–2031
adagrasib
'19
'20
'21
'22
'23
'24
'25
'26
'27
'28
'29
'30
'31
adagrasib
Genetic Testing in Guiding Treatment for Patients With Brain MetastasesP2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7P2
KRYSTAL-12P3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)P3
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationP2
Neo-KanP2
ADEPPTP2
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabP2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)P2
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesP2
Krascendo 1P3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)P3
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialP2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesP2
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerP2
Upcoming readouts
9 ahead · adagrasib
Select a trial to load its full ClinicalTrials.gov record.
Key adagrasib trials
Top 12 of the 15 registered phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track adagrasib with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Related drug pipelines
FAQ
- How many clinical trials are running for adagrasib?
- ClinicalTrials.gov currently lists 15 phase 2–4 adagrasib trials: 11 phase 2, 4 phase 3, and 0 phase 4. 5 are actively recruiting.
- Are there clinical trials for Krazati?
- Krazati is the brand name for adagrasib, so adagrasib trials on ClinicalTrials.gov cover it. ClinicalTrials.gov currently lists 15 phase 2–4 adagrasib trials: 11 phase 2, 4 phase 3, and 0 phase 4. 5 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare adagrasib against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.